Skip to product information
1 of 1

FDA ANDA 210317, OCTREOTIDE ACETATE, TEVA PHARMS USA INC, 12/05/2023

FDA ANDA 210317, OCTREOTIDE ACETATE, TEVA PHARMS USA INC, 12/05/2023

Regular price $588.45 USD
Regular price Sale price $588.45 USD
Sale Sold out

Contents: Summary Basis of Approval and related FDA review documents for ANDA 210317 for OCTREOTIDE ACETATE approved on 12/5/2023.

ANDA: 210317
Company: TEVA PHARMS USA INC
Drug Name: OCTREOTIDE ACETATE
Active Ingredients: OCTREOTIDE ACETATE
Strength: EQ 30MG BASE/VIAL
Dosage Form/Route: INJECTABLE;INJECTION
Action Date: 12/05/2023
Marketing Status: Prescription
Submission Classification: ORIG-1
Action Date: AB

192 Pages

View full details
FOIA Pro

This drug has a lot more FDA history than one product page can show

FOIA Pro gives you full-text search across 70,000+ FDA FOIA records, from 2020 through today, plus a monthly monitor tracking new requests as they close.
  • Full-text search across every FDA FOIA log since 2020
  • Warning letters, approval records, and correspondence in one place
  • Monthly FDA FOIA Monitor newsletter, included
  • Cancel anytime, monthly or annual billing
Get FOIA Pro
Live search · FOIA database
Searching related FDA records…
ClosedTypeSubjectOutcome